# A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20

> **NCT07792941** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 12 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** tilrekimig and rHuPH20

## Key facts

- **NCT ID:** NCT07792941
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-27
- **Primary completion:** 2027-02-11
- **Final completion:** 2027-02-11
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07792941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07792941, "A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07792941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
